Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Telacebec

Phase 2Small molecule

QQurient Co., Ltd.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Buruli UlcerRecruiting

Buruli UlcerPhase 2

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Buruli Ulcer

NCT06481163

Clinical

Trials by Indication[1]

COVID-191 trial

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

Terminated·QQurient Co., Ltd.·Phase 2·NCT04847583·1 enrolled

Phase 21 trial

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Completed·QQurient Co., Ltd.·Phase 2·NCT03563599·60 enrolled

Buruli Ulcer1 trial

A Phase 2 Multicentre, Open-label Study to Evaluate the Efficacy, Safety and Tolerability, and Pharmacokinetics of 14 -28 Days Telacebec Treatment in Adult Participants With Buruli Ulcer.

Recruiting·BBarwon Health·Phase 2·NCT06481163·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Telacebec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telacebec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telacebec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qurient Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: QQurient Co., Ltd.

Related News